373 related articles for article (PubMed ID: 30715686)
1. Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.
Johnston KM; Walker DR; Lakzadeh P
Adv Ther; 2019 Mar; 36(3):548-562. PubMed ID: 30715686
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
6. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
[TBL] [Abstract][Full Text] [Related]
9. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.
Kinjo M; Yamaguchi T; Tambo M; Okegawa T; Fukuhara H
Urol Int; 2019; 102(3):331-335. PubMed ID: 30799398
[TBL] [Abstract][Full Text] [Related]
10. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
[TBL] [Abstract][Full Text] [Related]
13. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
[TBL] [Abstract][Full Text] [Related]
15. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.
Castro-Diaz D; Chapple CR; Hakimi Z; Blauwet MB; Delgado-Herrera L; Lau W; Mujais S
Qual Life Res; 2015 Jul; 24(7):1719-27. PubMed ID: 25688038
[TBL] [Abstract][Full Text] [Related]
16. The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
Wu T; Duan X; Cao CX; Peng CD; Bu SY; Wang KJ
Urol Int; 2014; 93(3):326-37. PubMed ID: 25115445
[TBL] [Abstract][Full Text] [Related]
17. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
18. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
19. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
20. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR
Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
